MedTrace Logo

Comparison of Concentration-time Course of Plasma and Intracellular Raltegravir in Healthy Volunteers

NCT01027182 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2010-03-19

No results posted yet for this study

Summary

The investigators hypothesize that the concentration-time profile of raltegravir is different in cells than that in plasma. Intracellular raltegravir concentrations may be higher and its half-life longer than in plasma. This may explain the efficacy of raltegravir despite variable plasma concentrations.

Conditions

  • Human Immunodeficiency Virus

Interventions

DRUG

Raltegravir

One 400mg tablet on day 1.

Sponsors & Collaborators

  • National University Hospital, Singapore

    collaborator OTHER

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Changi General Hospital

    lead OTHER

Principal Investigators

  • Edmund JD Lee, Professor · Changi General Hospital

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-12-31
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01027182 on ClinicalTrials.gov